Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,127 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04874844 | JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety | unknown | Phase 2 / Phase 3 | 420 | Beijing Dongfang Biotech Co., Ltd.INDUSTRY | 0 | May 10, 2021 | clinicaltrials |
| NCT02644252 | Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer(Toco-Pulm) | terminated | Phase 3 | 79 | Vejle HospitalOTHER | 1 | May 3, 2021 |
| NCT04829708 | Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy | recruiting | Phase 3 | 534 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT02990780 | Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC | unknown | Phase 3 | 266 | Shanghai Chest HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03296163 | A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLA) | completed | Phase 3 | 627 | mAbxience Research S.L.INDUSTRY | 18 | Apr 26, 2021 | clinicaltrials |
| NCT04840290 | A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC | unknown | Phase 3 | 30 | Tang-Du HospitalOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01244191 | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | terminated | Phase 3 | 1,048 | Daiichi SankyoINDUSTRY | 23 | Apr 6, 2021 | clinicaltrials |
| NCT02667743 | Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC | unknown | Phase 3 | 454 | Shanghai Yizhong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03668496 | A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC | unknown | Phase 3 | 390 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04797806 | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC(SAINT) | unknown | Phase 3 | 206 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04691063 | The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. | unknown | Phase 3 | 486 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04772287 | Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) | not yet recruiting | Phase 3 | 341 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Feb 26, 2021 | clinicaltrials |
| NCT00003606 | Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 3 | 216 | UNICANCEROTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04490421 | Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. | unknown | Phase 3 | 45 | Fuzhou General HospitalOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT02893332 | Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)(Sindas) | terminated | Phase 3 | 200 | Sichuan Provincial People's HospitalOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04500145 | Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer | unknown | Phase 3 | 350 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT00130728 | A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | completed | Phase 3 | 636 | Genentech, Inc.INDUSTRY | 1 | Jan 14, 2021 | clinicaltrials |
| NCT00662597 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer(ATRACT-1) | terminated | Phase 3 | 1,285 | Novartis PharmaceuticalsINDUSTRY | 26 | Dec 24, 2020 | clinicaltrials |
| NCT00738387 | A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer(ATTRACT-2) | terminated | Phase 3 | 900 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 24, 2020 | clinicaltrials |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | terminated | Phase 3 | 2,278 | GlaxoSmithKlineINDUSTRY | 34 | Dec 22, 2020 | clinicaltrials |
| NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer | terminated | Phase 3 | 185 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT01639001 | A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients | completed | Phase 3 | 207 | PfizerINDUSTRY | 5 | Dec 8, 2020 | clinicaltrials |
| NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.(PIONEER) | terminated | Phase 3 | 600 | CTI BioPharmaINDUSTRY | 11 | Nov 24, 2020 | clinicaltrials |
| NCT00410683 | Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery(LUNG ART) | unknown | Phase 3 | 500 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT01355497 | Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum | completed | Phase 3 | 330 | GTxINDUSTRY | 1 | Nov 9, 2020 | clinicaltrials |
| NCT03402048 | The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial(EPIC) | unknown | Phase 3 | 567 | University of Turin, ItalyOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT03288870 | Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)(DOMINUS) | unknown | Phase 2 / Phase 3 | 218 | BiocadINDUSTRY | 2 | Oct 29, 2020 | clinicaltrials |
| NCT00128102 | Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) | completed | Phase 3 | 661 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 26, 2020 | clinicaltrials |
| NCT00576225 | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04237090 | Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel(PREMED-F1) | completed | Phase 3 | 27 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT00054184 | Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer | terminated | Phase 3 | 350 | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00054197 | Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | — | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00054210 | Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | — | CTI BioPharmaINDUSTRY | 2 | Oct 5, 2020 | clinicaltrials |
| NCT00551733 | Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 450 | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00880971 | Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer | completed | Phase 3 | 394 | Chinese Academy of Medical SciencesOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01544179 | A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone(IMPRESS) | completed | Phase 3 | 265 | AstraZenecaINDUSTRY | 11 | Sep 25, 2020 | clinicaltrials |
| NCT04535739 | PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study | unknown | Phase 3 | 414 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT04416035 | A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC(NSCLC) | unknown | Phase 3 | 608 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04500704 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC(ACROSS1) | unknown | Phase 3 | 166 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500717 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation(ACROSS2) | unknown | Phase 3 | 460 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT02395172 | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | completed | Phase 3 | 792 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 29 | Aug 3, 2020 | clinicaltrials |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer(RATIONALE001) | terminated | Phase 3 | 1 | CelgeneINDUSTRY | 23 | Jul 15, 2020 | clinicaltrials |
| NCT04465968 | Efficacy and Safety of CRT, Durvalumab and Surgery for SST(DEEP_OCEAN) | not yet recruiting | Phase 3 | 84 | National Cancer Center Hospital EastOTHER | 0 | Jul 10, 2020 | clinicaltrials |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | completed | Phase 3 | 1,351 | Bristol-Myers SquibbINDUSTRY | 34 | Jul 8, 2020 | clinicaltrials |
| NCT02361099 | SENTINEL : Impact of the Use of a Web-application for the Detection of Lung Cancer Relapse(SENTINEL) | completed | Phase 3 | 133 | WepromOTHER | 1 | Jun 29, 2020 | clinicaltrials |
| NCT02004184 | Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy(IDA) | terminated | Phase 3 | 230 | Norwegian University of Science and TechnologyOTHER | 1 | Jun 23, 2020 | clinicaltrials |
Data updated 24 days agoSource updated May 10, 2021source: clinicaltrials